A Vertex Pharmaceuticals drug viewed as a successor to a non-opioid pill that won a landmark FDA approval earlier this year has failed a mid-stage clinical trial, dealing a setback to the company’s ...

Company shares surged in after-market trading on results for a drug Vertex acquired in a multibillion-dollar deal and sees as ...

Vertex Pharmaceuticals will soon try to commercialize another medicine. The new therapy targets the same market as four of its other products. Using a priority review voucher is an expensive choice, ...

Vertex Pharmaceuticals Inc. shares rose after the biotech company said its drug to treat a kidney disorder met its goal in a ...

Vertex Pharmaceuticals Inc. fell after an experimental pain drug failed to provide post-surgery benefits and US regulators said they didn’t see a path forward for broad use of its pill in treating a ...

New phase 4 data from Vertex Pharmaceuticals revealed that more than 90% of patients recovering from aesthetic or reconstructive surgery remained opioid-free when treated with Journavx (suzetrigine) ...

Vertex just won approval for a drug to treat one of the most common health problems -- pain. The biotech company is offering an option for patients and doctors who don’t want to go for controversial ...